NCT05668377 is a clinical trial of PulseAI ECG Platform in Arrhythmias, Cardiac, sponsored by PulseAI Ltd.

Who is sponsoring NCT05668377?

NCT05668377 is sponsored by PulseAI Ltd.

What drugs are being tested in NCT05668377?

Interventions in NCT05668377: PulseAI ECG Platform.

What condition does NCT05668377 study?

NCT05668377 studies Arrhythmias, Cardiac.

Is NCT05668377 still recruiting?

NCT05668377 is currently status unknown. Last updated 29 December 2022.

Last reviewed 2022-12-29 · How we verify

NCT05668377

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Automated Diagnostic Performance of Smartwatch ECG for Arrhythmia Detection Using the PulseAI Neural Network.

Status unknown Last updated 29 December 2022

What this trial tests

trial testing PulseAI ECG Platform in Arrhythmias, Cardiac in 300 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
1 January 2024

1 January 2024

Quick facts

Lead sponsor	PulseAI Ltd
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 January 2023
Primary completion	1 January 2024
Estimated completion	1 January 2024
Sites	1 location across Ireland

Drugs / interventions tested

PulseAI ECG Platform

Conditions studied

Arrhythmias, Cardiac — all drugs for Arrhythmias, Cardiac →

Sponsor

PulseAI Ltd

Who can join

Adults 22 to 80, any sex, with Arrhythmias, Cardiac. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is to evaluate the performance of the PulseAI neural network technology at interpreting ECG data recorded using a single-lead Smartwatch (Apple Watch).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Arrhythmias, Cardiac

Currently open trials in the same condition.

NCT07276139 — PACEVALUE: Development of a Risk Score to Predict Pacing-Induced Cardiomyopathy in Patients Undergoing Pacemaker or ICD · active not recruiting
NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation · recruiting
NCT06360939 — Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease · NA · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06358391 — To Compare and Evaluate the Efficacy and Safety Between TS-RF System and BRK Transseptal Needles Used for Transseptal Pu · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05668377 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PulseAI Ltd
Last refreshed: 29 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05668377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing